Regenerative medicine using stem cells stands at the forefront of innovation in health care, offering the potential to treat various medical conditions. Yet, despite the promise of this science, recent federal policy changes have created new barriers to funding, conducting, and approving clinical trials and therapies, posing significant challenges to advancing patient care.
This installment of the Baker Institute’s annual policy lecture series brought together physician-scientist Dr. Emerson Perin and patient advocate Micaela Alpert, who discussed the future of regenerative medicine. The conversation explored how to streamline regulatory processes, accelerate the review and approval of clinical protocols, and secure funding for research. Hosted by the Baker Institute's Science and Technology Policy Program and co-sponsored by the Center for Health Policy and The Texas Heart Institute, this event was supported by a grant from the George and Mary Josephine Hamman Foundation.
It was free and open to the public.
Follow @BakerInstitute on X to join the conversation online with #BakerLive.
Registration
Registration has closed.
Baker Institute events are powered by the generous contributions of our supporters. Learn how you can make a donation or become a member of the Baker Roundtable.
Agenda
7:30 am CDT — Reception
8:00 am CDT — Welcome Remarks
8:00 am CDT — Speaker 1 Remarks
8:30 am CDT — Speaker 2 Remarks
8:55 am CDT — Q&A Session
9:25 am CDT — Closing Remarks
Participants
Welcome Remarks
Kirstin R.W. Matthews, Ph.D.
Fellow in Science and Technology Policy, Baker Institute
Panelists
Dr. Emerson Perin
Director, Center for Clinical Research and Stem Cell Center; Medical Director, The Texas Heart Institute
Micaela Alpert
Medical Student, Perelman School of Medicine at the University of Pennsylvania
Moderator
The Honorable David M. Satterfield
Director, Rice University’s Baker Institute for Public Policy; Janice and Robert McNair Chair in Public Policy; Former Ambassador to Lebanon and Turkey
Related Events
